Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC
Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with ... Read More
Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More
LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus ... Read More
Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration
Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's Retevmo (selpercatinib) capsules for the treatment of three ... Read More
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers
Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and ... Read More